360dx.com

Roche Cobas Mass Spec gets first US customer as CLIA clearances expand

Roche logoRoche
Sig2.70Sen+1.80Env0.00Soc+1.30Gov+0.80

Roche’s Cobas Mass Spec is a fully automated sample-to-answer system designed to run like a routine clinical analyzer, reducing the expert personnel typically needed for mass spectrometry testing. After launching in Europe in late 2024, Roche placed a system with its first US customer, Laboratory Corporation of America, and aims for 100 installed instruments. In the US it has CLIA categorization for six steroid tests and a Vitamin D assay, with more clearances expected through 2027.

Coverage (1)

ABOUT

What is Fimmer?

Most feeds treat all company headlines the same. An executive interview, an office closure, stock analysis, and a data breach can sit side by side with no sense of scale. Fimmer ranks coverage by what matters, so important events stand out and signals are prioritised over noise. We cluster related company news and score each story using a range of metrics, so you see the most crucial stories first.

SCORING

What do the scores mean?

Significance (0–10) measures the scale of the real-world impact. Sentiment and ESG (−10 to +10) indicate the tone of the coverage and whether the change relates to environmental, social, or governance factors. Together, these scores help distinguish meaningful developments from routine company news. More information about our scoring methodology can be found on our About page.

DISCOVERY

Explore more on Fimmer

Search more than 10,000 public companies, browse the company index, explore their scores, and read the coverage behind them, with our core features available to everyone for free.

For more advanced features, Pro gives you access to dynamic feeds, custom sorting, and more ways to track the companies that matter to you.

More with Pro